Zimmer Biomet was dragging down the S&P Health Care sector Monday morning after cutting its sales guidance for the year.
CNBC's Meg Tirrell reports on the best biotech performers year-to-date. Sam Isaly, OrbiMed Advisors managing partner, shares his take on the biotech sector, including his bargain stock picks.
It is currently the only sector in the S&P 500 that is negative year to date.
Stocks that would do well in the event of a GOP presidential victory are no longer lagging the Clinton stocks as much as they had been.
If you think more record highs are on the horizon for the Nasdaq, Deirdre Bosa breaks down the best historical ways to play it.
Using Kensho, we screened for the best trades if the Nasdaq index continues to climb.
CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.
Jim Cramer highlights one group that was a clear winner of the first half of 2016.
Finding stock picks in the market rally, with Mariann Montagne, Gradient Investments senior investment analyst, and John Canally, LPL Financial investment strategist and economist.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including Alexion and Manpower.
What are the 5 stocks that Wall Street is most bullish on? Eddy Elfenbein of “Crossing Wall Street” blog and Craig Johnson of Piper Jaffray discuss if they’re worth a look with Brian Sullivan.
Shares of Alexion fell nearly 12 percent Monday after the pharmaceutical company said it missed its goal in a late-stage trial of the drug Solaris.
U.S. stocks closed mixed Tuesday, with health care leading decliners and energy leading as oil settled above $50 a barrel for the first time since July.
CNBC's Meg Tirrell looks at some pharma and biotech stocks that are making news today.
Check out the companies making headlines after the bell Monday: Sarepta, Alexion, Whole Foods and more.
CNBC's Deirdre Bosa uses Kensho data to check on a potential impact of falling copper prices.
Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.
Jim Cramer gives his take on various caller favorite stocks, including this biotech that could roar if the market heads higher.
A group of up-trending ETFs could be ready to move even higher, should analyst forecasts for the individual holdings come to fruition.
Amid the wreckage in the retail sector, is now the time to cherry-pick some of the names that may have been unfairly punished?